# Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

> **NCT05943496** · PHASE1 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 27 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Acalabrutinib
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography
- **BIOLOGICAL:** Obinutuzumab
- **OTHER:** Questionnaire Administration
- **BIOLOGICAL:** Tafasitamab

## Key facts

- **NCT ID:** NCT05943496
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05943496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05943496, "Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05943496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*